Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products)

重组抗HER2人源化单抗（上海生物制品研究所）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products)
Drug Alias Name重组抗HER2人源化单克隆抗体（上海生物制品研究所）注射用重组抗HER2人源化单抗（上海生物制品研究所）SIBP-01
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsStomach NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Institute of Biological Products Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Institute of Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A